Segment Data (Schedule of Net Sales from External Customers by Products) (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2017	Jun. 24, 2016	Jun. 30, 2017	Jun. 24, 2016
Segment Reporting Information
Net sales		$ 824.5	$ 866.6	$ 1,635.4	$ 1,682.4
Operating Segments
Segment Reporting Information
Net sales		810.5	852.7	1,606.3	1,652.1
Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		594.5	589.3	1,151.7	1,124.3
Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		216.0	263.4	454.6	527.8
Corporate, Non-Segment
Segment Reporting Information
Net sales	[1]	14.0	13.9	29.1	30.3
Acthar | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		319.4	298.3	591.2	546.7
Inomax | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		125.5	121.1	253.9	236.6
Ofirmev | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		75.7	70.7	149.1	141.8
Therakos immunotherapy | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		51.2	52.5	102.4	102.7
Hemostasis Products | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		13.5	13.9	26.6	25.3
Other | Operating Segments | Specialty Brands
Segment Reporting Information
Net sales		9.2	32.8	28.5	71.2
Other | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		40.0	45.6	95.1	84.8
Hydrocodone (API) and hydrocodone-containing tablets | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		23.0	38.2	53.3	79.0
Oxycodone (API) and oxycodone-containing tablets | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		25.1	30.6	47.2	68.5
Methylphenidate ER | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		20.2	24.3	43.9	48.9
Other Controlled Substances | Operating Segments | Specialty Generics
Segment Reporting Information
Net sales		$ 107.7	$ 124.7	$ 215.1	$ 246.6

[1] Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.